share_log

Field Trip Health & Wellness Ltd. Reports Fiscal First Quarter 2023 Financial and Operating Results

Field Trip Health & Wellness Ltd. Reports Fiscal First Quarter 2023 Financial and Operating Results

菲尔德Trip Health&Wellness Ltd.报告2023财年第一季度财务和经营业绩
GlobeNewswire ·  2022/08/29 17:05
  • Completed corporate reorganization on August 11, 2022 separating the drug development ("Reunion Neuroscience Inc." or "Reunion") and healthcare and wellness ("Field Trip Health & Wellness" or "Field Trip") divisions into two separate public companies (the "Spinout Transaction").
  • Field Trip received listing approval from the TSX Venture Exchange ("TSX-V") and commenced trading on August 17, 2022 under new ticker symbol "FTHW".
  • Concurrent with the closing of the Spinout Transaction, completed a series of private placement financings for gross proceeds of approximately $20 million, led by Oasis Management Company and Reunion, positioning Field Trip to continue to lead this new market.
  • Field Trip generated revenues of $1.8 million during the quarter ended Jun 30, 2022, an increase of 110% over prior year's first fiscal quarter.
  • In May 2022 launched 'Field Trip at Home Powered by Nue Life', an innovative wellness platform for personalized, at-home psychedelic care through providing ketamine treatments, an interactive companion app, and virtual aftercare programs as an alternative to in-clinic care.
  • 于2022年8月11日完成了公司重组,分离了药物开发(“留尼汪神经科学公司”)。或“团圆”)和医疗保健与健康(“实地考察健康与健康”或“实地考察”)部门合并为两家独立的上市公司(“拆分交易”)。
  • 菲尔德Trip获得了多伦多证券交易所创业板(“TSX-V”)的上市批准,并于2022年8月17日开始交易,新的股票代码为“FTHW”。
  • 在完成拆分交易的同时,完成了由绿洲管理公司和留尼汪岛牵头的一系列私募融资,总收益约为2000万美元,使FieldTrip定位为继续引领这一新市场。
  • 在截至2022年6月30日的季度里,野外旅行产生了180万美元的收入,比上一财年第一财季增长了110%。
  • 2022年5月推出了由Nue Life提供动力的家居实地旅行,这是一个创新的健康平台,通过提供氯胺酮治疗、互动同伴应用程序和虚拟后续护理计划作为诊所内护理的替代方案,为个性化的居家迷幻护理提供服务。

TORONTO, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Field Trip Health & Wellness Ltd. (TSXV: FTHW) (the "Company" or "Field Trip"), a global leader in the delivery of psychedelic therapies, reported fiscal first quarter 2023 results for the three-month period ended June 30, 2022, and provided a business update. All results are reported under International Financial Reporting Standards ("IFRS") and in Canadian dollars, unless otherwise specified.

多伦多,2022年8月29日(Global Newswire)--提供迷幻药物治疗的全球领先企业--菲尔德Trip Health&Wellness Ltd.(多伦多证券交易所股票代码:FTHW)(以下简称“公司”或“野外旅行”)公布了截至2022年6月30日的三个月的2023财年第一季度业绩,并提供了业务最新情况。所有业绩均根据国际财务报告准则(“国际财务报告准则“)和加元,除非另有说明。

During the quarter, Field Trip continued to deliver innovative psychedelic-assisted therapies across its 12 operating clinics, achieving increased revenue growth of 110% over the prior year's first fiscal quarter. Revenue growth was driven by continued operational improvements, enhanced digital marketing, expanded service offerings and increased conversion of new clients.

在本季度,FieldTrip继续在其12家运营诊所提供创新的迷幻辅助疗法,实现了比上一财年第一财季增长110%的收入增长。收入增长是由持续的运营改善、增强的数字营销、扩大的服务提供和更多的新客户转换推动的。

To date, Field Trip's focus has been on delivering in-person care through its 12 centres. Over the next twelve months, the Company will expand its focus to offer a blend of both digital and in-clinic experiences, providing a more holistic wellbeing and lifestyle approach to mental health. Through its leading digital psychedelic platform, Field Trip has already created a large, engaged community which provides access to therapies both inside and outside clinical settings. Going forward, Field Trip will leverage the data and learnings from these tools to bring therapies and community support to people at scale.

到目前为止,野外旅行的重点一直是通过其12个中心提供面对面的护理。在接下来的12个月里,该公司将扩大其重点,提供数字和临床体验的融合,为精神健康提供更全面的福祉和生活方式。通过其领先的数字迷幻平台,FieldTrip已经创建了一个大型的参与式社区,提供临床环境内外的治疗途径。展望未来,实地旅行将利用这些工具的数据和经验教训,为人们带来大规模的治疗和社区支持。

During the quarter, Field Trip launched its 'Field Trip at Home™ Powered by Nue Life' platform, which allows patients to access guided ketamine treatments from the comfort of their home, as an alternative to in-clinic care. Field Trip is now able to provide more convenient and accessible treatment options and will continue to build communities and tools that help to create and sustain lasting wellbeing.

在本季度,FieldTrip推出了由Nue™提供支持的家庭实地旅行平台,允许患者在舒适的家中获得有指导的氯胺酮治疗,作为临床护理的替代方案。实地考察旅行现在能够提供更方便和可获得的治疗选择,并将继续建立社区和工具,帮助创造和维持持久的福祉。

Ronan Levy, Chairman and Chief Executive Officer of Field Trip Health & Wellness, stated, "When we launched Field Trip four years ago, our mission was to trailblaze a path for psychedelic medicine and bring these therapies into the mainstream. We are now happy to say we have achieved that objective. As a standalone company, we plan to lead a whole new approach to mental and emotional health and well-being - one that recognizes that depression and anxiety are not just functions of our brains, but also very much a function of how we live our lives."
Mr. Levy continued, "Going forward, we will build upon our already successful psychedelic-assisted therapy programs at our best-in-class Field Trip Health centers that are generating unparalleled outcomes in depression and anxiety treatments. We are now taking a much more holistic view of mental and emotional health and wellbeing, integrating technology, medicine and community to change how we approach mental health and wellbeing. This multifaceted approach will help people dive into self-discovery and self-awareness, to find their motivations, discover their passions and find the freedom to be happy, connected, free from depression and anxiety and, simply, to be themselves."

野外旅行健康与健康公司董事长兼首席执行官罗南·利维表示:“四年前,当我们推出实地旅行时,我们的使命是开辟一条致幻药物的道路,并将这些疗法带入主流。现在我们很高兴地说,我们已经实现了这一目标。作为一家独立的公司,我们计划引领一种全新的心理和情绪健康与福祉方法--认识到抑郁和焦虑不仅是我们大脑的功能,而且在很大程度上也是我们生活方式的一种功能。”
利维继续说,“展望未来,我们将在我们一流的野外旅行健康中心开展的迷幻辅助治疗项目的基础上再接再厉,这些项目在抑郁症和焦虑症的治疗方面产生了无与伦比的效果。我们现在对心理和情绪健康与福祉有了更全面的看法,整合了技术、医学和社区,以改变我们对待心理健康和幸福的方式。这种多方面的方法将帮助人们深入自我发现和自我意识,找到他们的动机,发现他们的激情,找到快乐、相互联系、摆脱抑郁和焦虑的自由,简单地做他们自己。”

Financial Highlights

财务亮点

Upon closing of the Spinout Transaction, Field Trip held approximately $17.2 million in unrestricted cash.

在Spinout交易完成后,field Trip持有约1720万美元的无限制现金。

For the fiscal first quarter ended June 30, 2022, the Clinics business generated patient services revenues of $1.8 million from its twelve clinics, representing an increase of 6% over the prior quarter and 110% over the comparative first fiscal quarter of the prior year. The growth in revenue was driven by the addition of six clinics and an increase in the volume of patient visits.

在截至2022年6月30日的第一财季,诊所业务从其12家诊所产生了180万美元的患者服务收入,比上一季度增长了6%,比上一财年第一财季增长了110%。收入的增长是由增加了六家诊所和病人就诊量的增加推动的。

Net loss for the clinics in the first fiscal quarter 2023 was $8.2 million compared with a $9.1 million loss in the same period of the prior fiscal year. This decrease in the net loss was primarily due to a more favorable foreign exchange rate, partly offset by the increase in operating costs associated with operating 12 clinics during the quarter, compared to six clinics in the comparative quarter of the prior fiscal year.

这些诊所在2023年第一财季的净亏损为820万美元,而上一财年同期的亏损为910万美元。净亏损的减少主要是由于汇率更加有利,但与上一会计年度同期的6家诊所相比,本季度经营12家诊所的运营成本增加部分抵消了这一影响。

Operating expenses for the first fiscal quarter were $12 million, compared to $9.6 million for the prior comparable quarter. This increase was primarily due to $3.4 million in non-recurring costs: $2.4 million in Spinout Transaction costs and a $1.0 million impairment write-off of fixed assets arising from the deferral of future clinic openings.

第一会计季度的营业费用为1200万美元,而上一可比季度为960万美元。这一增长主要是由于340万美元的非经常性成本:240万美元的拆分交易成本和100万美元的固定资产减值冲销,这些减值冲销是由于推迟未来开设诊所而产生的。

"From an operations perspective, we are delighted to report another sequential quarter of revenue growth, while managing to reduce our recurring expenses by 30%," said Mujeeb Jafferi, President of Field Trip Health & Wellness. "We have continued to improve operational efficiencies at our health centres, automate several client acquisition processes and increase community engagement through our digital tools."

“从运营的角度来看,我们很高兴又一个季度实现了收入的增长,同时我们设法将经常性开支减少了30%,”野外旅行健康与健康公司的总裁Mujeeb Jafferi说。我们继续提高我们健康中心的运营效率,实现几个客户获取过程的自动化,并通过我们的数字工具增加社区参与度。

Conference Call
The Company will conduct a conference call and webcast to discuss its results the following morning, Tuesday, August 30, 2022 at 8:30 a.m. ET. To access the call, please dial 1-877-407-9716 (within the U.S.) or 1-201-493-6779 (outside the U.S.) and provide conference ID 13732491. A live webcast of the conference call can be accessed via the Events and Presentations section of the Field Trip Health Investor Relations website here.

电话会议
该公司将于2022年8月30日(星期二)上午8:30举行电话会议和网络直播,讨论其业绩。Et.要接听电话会议,请拨打1-877-407-9716(美国国内)。或1-201-493-6779(美国境外)并提供会议ID 13732491。通过现场旅行健康投资者关系网站的活动和演示部分,可以观看电话会议的现场网络直播。

For those unable to attend the live call, a telephonic replay will be available until 11:59 p.m. ET on Tuesday, September, 13 2022. To access the replay dial 1-844-512-2921 (within the U.S.) or 1-412-317-6671 (outside the U.S.) and provide conference ID 13732491. The webcast will be archived and available in the Events and Presentations section of the Field Trip Health Investor Relations website approximately one hour after the conclusion of the live call.

对于那些无法参加现场通话的人,电话重播将持续到晚上11:59。美国东部时间2022年9月13日星期二。要收听重播,请拨打1-844-512-2921(美国国内)或1-412-317-6671(美国境外)并提供会议ID 13732491。网络直播将在现场通话结束约一小时后存档,并在实地旅行健康投资者关系网站的活动和演示部分提供。

Selected Financial Information

精选财务信息

The following table sets forth selected financial information derived from the Company's unaudited combined carve-out financial statements for the fiscal first quarter 2023 ended June 30, 2022, prepared in accordance with IAS 34 in a manner consistent with the Company's annual audited combined carve-out financial statements. The following information should be read in conjunction with the financial statements and management's discussion and analysis, which are available on the Company's website at and under the Company's SEDAR profile at .

下表载列本公司截至2022年6月30日的未经审核综合分拆财务报表的精选财务资料,该等财务报表是根据国际会计准则第34号以符合本公司年度经审计合并分拆财务报表的方式编制的。以下信息应与财务报表和管理层的讨论和分析一起阅读,这些信息可在公司网站上和公司SEDAR简介下查阅。

  3 months ended   3 months ended  
  June 30, 2022   June 30, 2021  
  $   $  
Revenue 1,824,404   867,400  
Operating expenses 11,997,250   9,572,710  
Other income (expenses) 1,936,168   (427,924)  
Net loss (8,236,678)   (9,133,235)  
截至3个月 截至3个月
2022年6月30日 2021年6月30日
$ $
收入 1,824,404 867,400
运营费用 11,997,250 9,572,710
其他收入(费用) 1,936,168 (427,924)
净亏损 (8,236,678) (9,133,235)

About Field Trip Health & Wellness Ltd.

关于野外旅行健康与健康有限公司。

Field Trip Health & Wellness Ltd. is a global leader in psychedelic therapies. With health centres across North America and Europe, along with the digital and technological tools that will enable massive scale, we help people in need with a simple, evidence-based way to heal and heighten engagement with the world.

菲尔德旅行健康与健康有限公司是迷幻疗法的全球领先者。通过北美和欧洲各地的医疗中心,以及将实现大规模规模的数字和技术工具,我们以一种简单、循证的方式帮助有需要的人,治愈疾病并加强与世界的接触。

Learn more at and

了解更多信息,请访问和

Follow us on Twitter and Instagram: @fieldtriphealth.

在Twitter和Instagram上关注我们:@fieldtriphealth。

Cautionary Note Regarding Forward-Looking Information

关于前瞻性信息的注意事项

This release includes forward-looking information (within the meaning of Canadian securities laws and within the meaning of the United States Private Securities Litigation Reform Act of 1995) regarding the Company and its business. Often but not always, forward-looking information can be identified by the use of words such as "expect", "intends", "anticipated", "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would" or "will" be taken, occur or be achieved. Such statements are based on the current expectations and views of future events of the management of the Company and are based on assumptions and subject to risks and uncertainties. Although the management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the companies. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. Additional information relating to the Company, can be located on the SEDAR website at .

本新闻稿包括有关该公司及其业务的前瞻性信息(符合加拿大证券法和1995年美国私人证券诉讼改革法的定义)。前瞻性信息往往但不总是可以通过使用诸如“预期”、“打算”、“预期”、“相信”或这些词语和短语的变体(包括负面变体)来确定,或者声明某些行动、事件或结果“可能”、“可能”、“将”或“将”被采取、发生或实现。这些陈述是基于公司管理层对未来事件的当前预期和看法,是基于假设的,受风险和不确定因素的影响。尽管管理层认为这些陈述所依据的假设是合理的,但它们可能被证明是不正确的。本新闻稿中讨论的前瞻性事件和情况可能不会发生,可能会因影响这些公司的已知和未知风险因素和不确定性而大不相同。尽管公司试图确定可能导致实际行动、事件或结果与前瞻性陈述中描述的大不相同的重要因素,但可能还有其他因素导致行动、事件或结果与预期、估计或预期的不同。因此,读者不应过分依赖任何前瞻性陈述或信息。任何前瞻性陈述都不能得到保证。除适用的证券法要求外,前瞻性表述仅在作出之日发表,公司不承担任何公开更新或修改任何前瞻性表述的义务,无论是由于新信息、未来事件或其他原因。有关该公司的更多信息, 可在SEDAR网站上找到。

Neither TSX Venture Exchange, or its Regulation Services Provider, have approved the contents of this release or accept responsibility for the adequacy or accuracy of this release.

多伦多证券交易所创业板交易所或其监管服务提供商均未批准本新闻稿的内容,也未对本新闻稿的充分性或准确性承担责任。

CONTACTS:

联系人:

Field Trip Health & Wellness:
Ronan Levy
Chairman & CEO
(416) 505-0929
ronan@fieldtriphealth.com

实地考察健康与健康:
罗南·利维
董事长兼首席执行官
(416) 505-0929
邮箱:ronan@fieldtriphelth.com

Investor contacts:
Phil Carlson / Sophia Bashford
(646) 573-0776) / (929 246-7307)
KCSA Strategic Communications
fieldtripIR@kcsa.com

投资者联系方式:
菲尔·卡尔森/索菲亚·巴什福德
(646) 573-0776) / (929 246-7307)
KCSA战略传播
邮箱:fieldtripIR@kcsa.com

SOURCE Field Trip Health & Wellness

来源:野外旅行健康与健康


声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发